Ashton Leone, MPH, CCRP, CCRA
Clinical Research Manager
If you’ve ever wondered what fuels clinical research at UVA Ophthalmology, the answer isn’t just found in data or trial protocols — it’s in people like Ashton Leone, MPH, CCRP, CCRA, Clinical Research Manager, whose quiet determination and sharp coordination keep everything moving forward.
“It’s a team effort,” Ashton is quick to say. But those who work alongside her know that her deep investment in both patients and progress has helped the department become a hub for groundbreaking studies across the spectrum of eye care.
This past fall and winter were especially active seasons, with multiple long-term studies reaching meaningful milestones — and a slate of new trials launching just as spring approaches.
Recent Highlights
Apellis GALE Study
Led by Paul A. Yates, MD, PhD, this open-label extension of Syfovre for geographic atrophy showed preserved visual function at 36 months — a remarkable result. “What really stands out,” Ashton notes, “is the dedication of our four participants. They committed nearly five years to these studies. That kind of long-term involvement is extraordinary and so important.”
Epion Apricity Study
Under the leadership of Tara W. McGehee, MD, this Phase 3 trial explores a less invasive, epithelium-on approach to corneal cross-linking for keratoconus using Ribostat. “It’s exciting to see alternatives that might reduce discomfort and downtime for patients,” Ashton adds.
What’s Ahead
With spring on the horizon, Ashton and the clinical research team are looking ahead to a robust lineup of new trials:
UCSF LOTUS Study
Led by Arthi G. Venkat, MD, MS, this global, multi-center collaboration brings together 15 academic institutions to study infectious uveitis through intraocular fluid and tear collection. “This kind of research has the potential to uncover new biomarkers and guide future treatment,” says Ashton.
Dazdotuftide – Mechanism of Action
Tarsier TRS01 Study
Another Phase 3 study led by Dr. Venkat, this trial investigates TRS01 (dazdotuftide) drops for non-infectious anterior uveitis. The drug inhibits the NF-kB pathway and encourages a shift toward anti-inflammatory macrophages, a new mechanism of action with real promise.
Sanofi DFI18231 Study
Led by Dr. Yates, this Phase 1/2 trial will evaluate a one-time intravitreal gene therapy for geographic atrophy. SAR446597 aims to block C3 and C5 complement cascade activation — potentially slowing or halting disease progression with a single injection.
4DMT 4Front Study
Also under Dr. Yates’ leadership, this Phase 3 trial tests 4D150 against aflibercept for neovascular AMD. The investigational drug targets VEGFs A, B, C, and placental growth factor — offering a multi-faceted anti-VEGF approach.
“I’m incredibly proud of our team — our faculty, our coordinators, and especially our patients,” Ashton says. “Every person who participates in a study is helping advance care for others. It’s powerful.”
For alumni, faculty, and friends of the department, Ashton offers a warm invitation:
“If you know a patient who may qualify, or if you’re just curious to learn more, reach out. We’re always happy to talk about what’s happening — and where we’re headed.”
—
Contact:
Ashton Leone, MPH, CCRP, CCRA
Clinical Research Manager
AML7Q@virginia.edu